Daratumumab Now FDA Approved for Newly Diagnosed Transplant-Ineligible Myeloma Patients
Daratumumab is now FDA approved in combination with lenalidomide and dexamethasone for newly diagnosed myeloma patients who are not eligible to receive a stem cell transplant. Daratumumab was approved in the fall of 2015 and has been a very effective addition to the myeloma drug arsenal for patients. It was formerly approved for use after initial